US 11,672,771 B2
Beta-alethine, immune modulators, and uses thereof
Floyd Taub, Golden, CO (US); and Amanda Guth, Fort Collins, CO (US)
Assigned to AxImmune, Inc., Aurora, CO (US); and Colorado State University Research Foundation, Fort Collins, CO (US)
Appl. No. 16/347,005
Filed by AxImmune, Inc., Aurora, CO (US); and Colorado State University Research Foundation, Fort Collins, CO (US)
PCT Filed Nov. 3, 2017, PCT No. PCT/US2017/060005
§ 371(c)(1), (2) Date May 2, 2019,
PCT Pub. No. WO2018/085698, PCT Pub. Date May 11, 2018.
Claims priority of provisional application 62/470,571, filed on Mar. 13, 2017.
Claims priority of provisional application 62/449,090, filed on Jan. 22, 2017.
Claims priority of provisional application 62/439,024, filed on Dec. 24, 2016.
Claims priority of provisional application 62/432,663, filed on Dec. 11, 2016.
Claims priority of provisional application 62/417,992, filed on Nov. 4, 2016.
Prior Publication US 2020/0069616 A1, Mar. 5, 2020
Int. Cl. A61K 31/16 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 39/395 (2006.01); C12Q 1/6886 (2018.01)
CPC A61K 31/16 (2013.01) [A61K 9/0019 (2013.01); A61K 38/177 (2013.01); A61K 38/2013 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01)] 5 Claims
 
1. A method of treating cancer in a subject in need thereof, which comprises administering to the subject an effective amount of (1) β-alethine and (2) at least one immune modulator, wherein the at least one immune modulator is an anti-PD-1 antibody or antigen-binding fragment thereof, and wherein the cancer is melanoma or bladder cancer.